A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

NCT05784246 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: Mirikizumab IV
DRUG: Mirikizumab SC

Sponsor

Eli Lilly and Company